Trevi Therapeutics, Inc.
TRVI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $39,377 | $23,683 | $19,834 | $22,984 |
| G&A Expenses | $12,147 | $10,240 | $10,073 | $9,492 |
| SG&A Expenses | $12,147 | $10,240 | $10,073 | $9,492 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $51,524 | $33,923 | $29,907 | $32,476 |
| Operating Income | -$51,524 | -$33,923 | -$29,907 | -$32,476 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3,583 | $4,826 | $719 | -$1,485 |
| Pre-Tax Income | -$47,941 | -$29,097 | -$29,188 | -$33,961 |
| Tax Expense | -$30 | -$32 | -$36 | -$21 |
| Net Income | -$47,911 | -$29,065 | -$29,152 | -$33,940 |
| % Margin | – | – | – | – |
| EPS | -0.47 | -0.29 | -0.45 | -1.49 |
| % Growth | -62.1% | 35.6% | 69.8% | – |
| EPS Diluted | -0.47 | -0.29 | -0.45 | -1.49 |
| Weighted Avg Shares Out | 101,042 | 99,033 | 64,542 | 22,841 |
| Weighted Avg Shares Out Dil | 101,042 | 99,033 | 64,542 | 22,841 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,602 | $4,748 | $1,740 | $10 |
| Interest Expense | $4 | $391 | $780 | $1,202 |
| Depreciation & Amortization | $147 | $123 | $43 | $50 |
| EBITDA | -$47,790 | -$28,583 | -$27,982 | -$32,709 |
| % Margin | – | – | – | – |